Clinical Trials in Geneva, Canton of Geneva
72 recruiting
Showing 1–20 of 67 trials
Recruiting
Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Triple-Negative Breast Cancer
Merck Sharp & Dohme LLC1,530 enrolled288 locationsNCT06393374
Recruiting
Phase 1Phase 2
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled44 locationsNCT06445972
Recruiting
Phase 1Phase 2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled50 locationsNCT06469944
Recruiting
Not Applicable
Neurofeedback-based Visual Restoration Therapy
Visual Field Defect Homonymous Bilateral
Adrian Guggisberg14 enrolled2 locationsNCT07237412
Recruiting
Not Applicable
The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
Uterine Fibroid
University Hospital, Geneva30 enrolled1 locationNCT07173127
Recruiting
Phase 4
Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies
AntibioticsPeriodontal DiseasesPharmacokinetics
University of Geneva, Switzerland45 enrolled1 locationNCT04669717
Recruiting
Not Applicable
Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease
Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)Diffuse Coronary Artery Disease
University Hospital, Geneva150 enrolled1 locationNCT06710210
Recruiting
Phase 3
Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)
Influenza Disease; Flu
Dre Pauline Vetter484 enrolled1 locationNCT06653569
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled281 locationsNCT06925737
Recruiting
Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Solid TumorsHematologic Malignancies
Merck Sharp & Dohme LLC3,500 enrolled779 locationsNCT03486873
Recruiting
Phase 4
SWIFT - SWIss Factor XIII Trial in PPH
Postpartum ComplicationCoagulation DisorderPostpartum Hemorrhage+2 more
Christian Haslinger988 enrolled9 locationsNCT06481995
Recruiting
Not Applicable
Effect of Transcranial Random Noise Stimulation on the Performance in Language Tasks
Adrian Guggisberg90 enrolled1 locationNCT07554105
Recruiting
Investigation of Gastric Emptying by Gastric Ultrasonography in Diabetic Patients Treated With GLP-1 Receptors
Diabete Type 2RegurgitationPulmonary Aspiration During Anaesthetic Induction
University Hospital, Geneva38 enrolled1 locationNCT07506356
Recruiting
Not Applicable
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
Acute Heart Failure
Antonio Leidi222 enrolled5 locationsNCT06465498
Recruiting
Phase 3
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.172 enrolled44 locationsNCT07200908
Recruiting
Not Applicable
Linezolid Plus Standard of Care
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
University Hospital, Basel, Switzerland606 enrolled12 locationsNCT06958835
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled57 locationsNCT05319730
Recruiting
Phase 3
Benefits of ADHD Treatment in Detained People
ADHD
Stéphanie Baggio150 enrolled1 locationNCT05842330
Recruiting
Not Applicable
Testing a New Method to Improve Informed Consent in Prison Research
ADHD
Stéphanie Baggio100 enrolled2 locationsNCT06378281
Recruiting
Phase 1
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Advanced Solid TumorsMetastatic Solid Tumors
Merck Sharp & Dohme LLC178 enrolled25 locationsNCT05853367